Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

ClinicalTrials.gov ID: NCT03296098

Public ClinicalTrials.gov record NCT03296098. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Open-label, Non-comparative Study of the Safety and Contraceptive Efficacy of Continuous Daily Oral 10 mg of Ulipristal Acetate (UPA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral 10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary method of contraception.

Study identification

NCT ID: NCT03296098
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 2
Lead sponsor: Premier Research; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

Ulipristal acetate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 35 Years
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2020 (Estimated)
Primary completion: Jan 2022 (Estimated)
Completion: Dec 2022 (Estimated)
Last update posted: Nov 20, 2025

2020 – 2022

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Essential Access	Los Angeles	California	90010	—
University of California, Davis	Sacramento	California	95817	—
University of California, San Francisco	San Francisco	California	94110	—
University of Colorado	Denver	Colorado	80045	—
University of Hawaii	Honolulu	Hawaii	96826	—
University of Chicago	Chicago	Illinois	60637	—
Johns Hopkins Bayview Medical Center	Baltimore	Maryland	21224	—
Planned Parenthood League of Massachusetts	Boston	Massachusetts	02215	—
New York University, School of Medicine	New York	New York	10016	—
Columbia University	New York	New York	10032	—
University of Cincinnati	Cincinnati	Ohio	45267	—
University Hospitals of Cleveland MacDonald Women's Hospital	Cleveland	Ohio	44106	—
Oregon Health & Science University	Portland	Oregon	97239	—
University of Pennsylvania Medical Center	Philadelphia	Pennsylvania	19104	—
Univeristy of Pittsburgh School of Medicine	Pittsburgh	Pennsylvania	15213	—
Women & Infants Hospital of Rhode Island	Providence	Rhode Island	02905	—
University of Utah	Salt Lake City	Utah	84106	—
Eastern Virginia Medical School (EVMS)	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03296098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 20, 2025 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03296098 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →